You are browsing articles on the topic of General Archives - CardioExchange

Avatar of Richard Lehman, BM, BCh, MRCGP

Selections from Richard Lehman’s Literature Review: November 24th (24 Nov 2014)

Voices

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the PROTECT-AF trial, the association of inpatient vs. outpatient onset of STEMI with treatment and clinical outcomes, and more.

Avatar of Larry Husten, PHD

European Review Confirms Increased Risk with Ivabradine (24 Nov 2014)

News

Following a review provoked by troubling findings that emerged from a large clinical trial, the European Medicines Agency (EMA) is making several recommendations intended to lower the risk of heart problems linked to the heart-rate-lowering drug ivabradine. The drug is marketed by Servier in Europe under the brand names of Corlentor and Procoralan and is indicated for…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Encouraging Results for Two New Drugs for Hyperkalemia (21 Nov 2014)

News

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. In a phase 3 study, published online in the New England Journal of Medicine, researchers first randomized…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Encouraging Results For Two New Drugs For Hyperkalemia (21 Nov 2014)

News

Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.  

Avatar of John

Intention to Tweet: Does Social Media Exposure Matter for Journal Articles? (20 Nov 2014)

Voices

John Ryan, MD

Research on Circulation’s own published articles suggests that it probably does not.

Avatar of Larry Husten, PHD

U.S. Proposal Would Greatly Expand Transparency of Clinical Trials (19 Nov 2014)

News

The U.S. Department of Health and Human Services today proposed new rules that would greatly expand the number of clinical trials that companies and researchers are required to report. “Medical advances would not be possible without participants in clinical trials,” said NIH Director Francis Collins. “We owe it to every participant and the public at large…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Losartan No Better Than Atenolol in Marfan’s Syndrome (18 Nov 2014)

News

Beta-blockers have been the standard treatment for people with Marfan’s syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people. The goal of treatment is to prevent or slow down the dilation of the aorta and avoid aortic dissection, the main cause of death. In recent years, studies have raised the…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Don’t Count the Numbers. HDL Function Looks Like the Key (18 Nov 2014)

News

A new study offers important evidence explaining the protective role of HDL cholesterol against cardiovascular disease. Previous studies with drugs that increase HDL levels, including niacin and CETP inhibitors, have not been found beneficial. The new study suggests that simply increasing HDL levels isn’t useful. Instead, cholesterol efflux, the ability of HDL to remove cholesterol from…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Larry Husten, PHD

Large Japanese Trial Casts Further Doubt on Aspirin for Primary Prevention (17 Nov 2014)

News

A large trial from Japan failed to provide any evidence to support the use of routine aspirin in high-risk elderly people to prevent a first cardiovascular event. The Japanese Primary Prevention Project (JPPP),  presented at the American Heart Association meeting in Chicago and published simultaneously in JAMA, enrolled patients between 60 and 85 years of age with hypertension, dyslipidemia,…

This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.

Avatar of Richard Lehman, BM, BCh, MRCGP

Selection from Richard Lehman’s Literature Review: November 17th (17 Nov 2014)

Voices

Richard Lehman, BM, BCh, MRCGP

This week’s topic is anticoagulant therapy during primary PCI for acute MI.